Security
Royalty Pharma plc Class A Ordinary Shares · RPRX
RPRXNASDAQCommon stockCurrentCIK 1802768Updated Oct 3, 2026
RPRX price & chart
Loading TradingView…
NASDAQ:RPRX on TradingView ↗About the company
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 16 development-stage p…
In the news
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen ↗
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 19,620,780,000Source | 18,222,715,000Source | 16,381,851,000Source | 16,813,466,000Source |
| GoodwillUSD | 924,634,000Source | — | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 618,696,000Source | 929,026,000Source | 477,010,000Source | 1,710,751,000Source |
| Assets, CurrentUSD | 1,528,091,000Source | 1,802,139,000Source | 1,274,193,000Source | 2,554,908,000Source |
| Other Assets, NoncurrentUSD | 79,293,000Source | 33,534,000Source | 6,522,000Source | 29,629,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 9,905,841,000Source | 7,880,349,000Source | 6,297,562,000Source | 7,288,093,000Source |
| Stockholders’ equity: | ||||
| Additional Paid in CapitalUSD | 4,123,088,000Source | 4,103,482,000Source | 4,011,435,000Source | 3,666,160,000Source |
| Retained Earnings (Accumulated Deficit)USD | 2,356,318,000Source | 2,845,653,000Source | 2,517,583,000Source | 1,964,689,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | 0Source |
| Liabilities and EquityUSD | 19,620,780,000Source | 18,222,715,000Source | 16,381,851,000Source | 16,813,466,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 636,211,000Source | 1,253,616,000Source | 161,377,000Source | 1,166,783,000Source |
| Other Liabilities, NoncurrentUSD | 120,843,000Source | 12,080,000Source | 900,000Source | 2,500,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 3,238,039,000Source | 3,395,785,000Source | 3,557,792,000Source | 3,897,223,000Source |
| Additional Financial Items | ||||
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | 6,135,285,000Source | — |
| Long-term Debt, Current MaturitiesUSD | 380,000,000Source | 997,773,000Source | 0Source | 997,512,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 8,570,917,000Source | 6,614,653,000Source | 6,135,285,000Source | 6,118,810,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 1,324,192,000Source | 1,330,813,000Source | 1,700,088,000Source | 230,064,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 289,894,000Source | 2,344,000Source | 2,357,000Source | 2,170,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 2,489,823,000Source | 2,768,986,000Source | 2,987,802,000Source | 2,143,980,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 74,416,000Source | — | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -1,614,180,000Source | -2,678,115,000Source | -2,072,789,000Source | -1,029,421,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | 8,946,000Source | -2,039,000Source | 2,038,000Source | — |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 1,227,383,000Source | 229,651,000Source | 304,759,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -1,185,973,000Source | 361,145,000Source | -2,148,754,000Source | -944,856,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | -1,790,000Source | -9,026,000Source | — | — |
| Repayments of Long-term DebtUSD | — | — | — | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -310,330,000Source | 452,016,000Source | -1,233,741,000Source | 169,703,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 618,696,000Source | 929,026,000Source | 477,010,000Source | 1,710,751,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 276,291,000Source | 159,570,000Source | 169,168,000Source | 170,139,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 290,890,000Source | — | — | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | 22,440,000Source | 19,562,000Source | 20,499,000Source | 21,356,000Source |
| Amortization of Intangible AssetsUSD | — | 0Source | 0Source | 5,670,000Source |
| DepreciationUSD | 3,852,000Source | — | — | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | -21,852,000Source | 39,549,000Source | 87,139,000Source | -33,442,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | 0Source | -6,000,000Source | -2,290,000Source | 96,610,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | 0Source | 0Source | -419,000Source |
| General and Administrative ExpenseUSD | 573,481,000Source | 236,671,000Source | 249,748,000Source | 227,303,000Source |
| GoodwillUSD | 924,634,000Source | — | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | 29,089,000Source | 29,611,000Source | 28,882,000Source | -8,973,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 307,664,000Source | 225,512,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 770,947,000Source | 858,983,000Source | 1,134,834,000Source | 42,832,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 553,245,000Source | 471,830,000Source | 565,254,000Source | 187,232,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 770,947,000Source | 858,983,000Source | 1,134,834,000Source | 42,832,000Source |
| Nonoperating Income (Expense)USD | -235,326,000Source | 38,369,000Source | 207,938,000Source | -77,001,000Source |
| Other Nonoperating Income (Expense)USD | -14,349,000Source | -1,528,000Source | -21,737,000Source | -14,755,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | 0Source |
| Financing Receivable, Credit Loss, Expense (Reversal)USD | 26,163,000Source | 100,415,000Source | 22,285,000Source | -193,798,000Source |
| Unrealized Gain (Loss) on DerivativesUSD | 0Source | -6,000,000Source | -2,290,000Source | 96,610,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 2,378,193,000Source | 2,263,576,000Source | 2,354,554,000Source | 2,237,215,000Source |
| Operating Income (Loss)USD | 1,559,518,000Source | 1,292,444,000Source | 1,492,150,000Source | 307,065,000Source |
| Other Nonoperating Income (Expense)USD | -14,349,000Source | -1,528,000Source | -21,737,000Source | -14,755,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 1,324,192,000Source | 1,330,813,000Source | 1,700,088,000Source | 230,064,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 553,245,000Source | 471,830,000Source | 565,254,000Source | 187,232,000Source |
| Net Income (Loss) Attributable to ParentUSD | 770,947,000Source | 858,983,000Source | 1,134,834,000Source | 42,832,000Source |
| Earnings Per Share, BasicUSD per share | 1.79Source | 1.92Source | 2.54Source | 0.1Source |
| Earnings Per Share, DilutedUSD per share | 1.78Source | 1.91Source | 2.53Source | 0.1Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 429,801,000Source | 448,185,000Source | 447,601,000Source | 437,963,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 564,455,000Source | 594,108,000Source | 602,900,000Source | 437,972,000Source |
| Interest Expense (non-operating)USD | 307,664,000Source | 225,512,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | 0Source | 0Source | 5,670,000Source |
| Business Combination, Acquisition Related CostsUSD | 28,900,000Source | — | — | — |
| Costs and ExpensesUSD | 818,675,000Source | 971,132,000Source | 862,404,000Source | 1,930,150,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | 0Source | -6,000,000Source | -2,290,000Source | 96,610,000Source |
| General and Administrative ExpenseUSD | 573,481,000Source | 236,671,000Source | 249,748,000Source | 227,303,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 29,089,000Source | 29,611,000Source | 28,882,000Source | -8,973,000Source |
| Interest ExpenseUSD | — | — | 187,187,000Source | 187,961,000Source |
| Interest Income, OtherUSD | 33,591,000Source | 47,343,000Source | — | — |
| Investment Income, NetUSD | — | — | 72,291,000Source | 78,335,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 770,947,000Source | 858,983,000Source | 1,134,834,000Source | 42,832,000Source |
| Nonoperating Income (Expense)USD | -235,326,000Source | 38,369,000Source | 207,938,000Source | -77,001,000Source |
| Research and Development ExpenseUSD | 452,000,000Source | 2,000,000Source | 52,000,000Source | 177,106,000Source |
Filing attachments
d58607dex43.htm · 8-K · 2025-09-16
EX-4.3 3 d58607dex43.htm EX-4.3 EX-4.3 Exhibit 4.3 FIFTH SUPPLEMENTAL INDENTURE Dated as of September 16, 2025 Supplementing that Certain INDENTURE Dated as of September 2, 2020 Among ROYALTY PHARMA PLC, ROYALTY PHARMA HOLDINGS LTD, ROYALTY PHARMA MANAGER, LLC and WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee 4.450% Senior Notes due 2031 5.200% Senior Notes due 2035 5.950% Senior Notes due 2055 TABLE OF CONTENTS …
Read attachment ↗d930454dex991.htm · 8-K · 2025-08-13
EX-99.1 2 d930454dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 HENRY FERNANDEZ STEPS DOWN FROM ROYALTY PHARMA’S BOARD OF DIRECTORS NEW YORK, NY, August 13, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Director in March 2021. “We are treme…
Read attachment ↗d90343dex991.htm · 8-K · 2025-08-06
EX-99.1 2 d90343dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 ROYALTY PHARMA REPORTS SECOND QUARTER 2025 RESULTS Portfolio Receipts growth of 20% to $727 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $364 million Raised full year 2025 guidance: Portfolio Receipts expected to be $3,050 to $3,150 million NEW YORK, NY, August 6, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2025 and raised full ye…
Read attachment ↗d948144dex991.htm · 8-K · 2025-07-17
EX-99.1 2 d948144dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 PRESS RELEASE ROYALTY PHARMA APPOINTS CAROLE HO AND ELIZABETH WEATHERMAN TO THE COMPANY’S BOARD OF DIRECTORS Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90% Underscores Royalty Pharma’s commitment to enhanced corporate governance following acquisition of its external manager NEW YORK, NY, July 17, 2025 - Royalty Pharma plc (Nasdaq…
Read attachment ↗d943352dex991.htm · 8-K · 2025-04-10
EX-99.1 2 d943352dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 PRESS RELEASE ROYALTY PHARMA APPOINTS VLAD CORIC, M.D. TO THE COMPANY’S BOARD OF DIRECTORS NEW YORK, NY, April 8, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-ch…
Read attachment ↗d929959dex991.htm · 8-K · 2025-02-11
EX-99.1 2 d929959dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 ROYALTY PHARMA REPORTS Q4 AND FULL YEAR 2024 RESULTS Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024 Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 ───────────────────────────────────────────────────────────────── Net cash provided by operating activities of $743 million in Q4 2024 and $2,769 million for FY 2024 Full year 2025 guidance: Portfolio Receipts expected to be $2,900 …
Read attachment ↗